Back to Conference page
The 13th World Conference on Tobacco OR Health
Building capacity for a tobacco-free world
July 12-15, 2006, Washington, DC, USA
Objective: At the conclusion of this session, the participants will be able to:
1. Identify the reduction of health and safety risks as a key goal of product regulation.
2. Describe the continuum of risks and relative risks imposed by cigarettes, smokeless tobacco products and Nicotine Replacement Therapy (NRT) products.
3. Recognize that proposed US FDA tobacco regulatory legislation requires changes to ensure that all product users are adequately and accurately informed about the spectrum of risks imposed by different tobacco/nicotine products on the market, and that any legislation must seek to establish a level playing field for different tobacco/nicotine products.
Methods: A primary goal of any product regulation is to reduce the health and safety risks of the regulated products. Analysis reveals that cigarettes impose far greater risks to users than smokeless tobacco products, while NRT products pose even fewer risks. The US FDA already regulates NRT products, and proposed FDA tobacco regulatory legislation has been endorsed by Philip Morris and by several large health organizations.
Results: Analysis of the proposed FDA tobacco regulations, however, reveals that tobacco users would not be adequately or accurately informed that cigarettes impose far greater risks than smokeless tobacco products, and that even less hazardous NRT would continue being regulated far more restrictively than any tobacco product. Therefore, changes are needed to ensure that proposed FDA tobacco regulatory legislation would adequately and accurately inform users of comparable product risks, and to establish a level playing field for different tobacco and NRT products.